Skip to main content
. 2020 Sep 10;21(11):e50078. doi: 10.15252/embr.202050078

Figure 7. Combined expression of hMENA, AXL, and GAS6 correlated with decreased survival in PDAC and NSCLC cancers.

Figure 7

  1. Overall survival (OS) curves in pancreatic adenocarcinoma patients (PDAC) (n = 172) from The Cancer Genome Atlas (TCGA) showed that combined expression of AXL, GAS6, and ENAH (hMENA) is a prognostic signature in PDAC.
  2. Overall survival (OS) curves in lung squamous cancer patients (LUSC) (n = 501) from The Cancer Genome Atlas (TCGA) showed that combined expression of AXL, GAS6, and ENAH (hMENA) is a prognostic signature in LUSC.
Data information: In (A, B) patients were stratified in three groups on the basis of the AXL/GAS6/ENAH (left), AXL/GAS6 (middle), and ENAH (right) signature expression levels. P values are shown. Statistical significance was calculated by using the log‐rank test.